Research connects: Blood-based biomarker testing with Dr. Mari DeMarco and Dr. Natanya Russek

Diagnostic Breakthrough

Blood-based biomarker testing for Alzheimer's disease has surged in relevance following regulatory milestones in 2025. The U.S. Food and Drug Administration cleared tests like Fujirebio's Lumipulse in May and Roche's Elecsys in October, marking the first approvals for plasma assays that detect amyloid pathology. These developments address longstanding diagnostic hurdles, where traditional methods like positron emission tomography (PET) scans or cerebrospinal fluid analysis are costly, invasive, and limited in availability.

The real-world impact is profound for the estimated 55 million people worldwide living with dementia, a figure projected to triple by 2050 due to aging populations. Early detection via blood tests, which cost hundreds rather than thousands of dollars, could enable timely access to anti-amyloid treatments like lecanemab, potentially slowing cognitive decline. In the U.S. alone, Alzheimer's care expenses exceed $300 billion annually, with delays in diagnosis exacerbating burdens on families and healthcare systems.

Concrete stakes involve not just financial savings but also health outcomes. Studies show that biomarkers like the p-tau217/amyloid-beta ratio predict symptom onset with accuracy rivaling PET, within three to four years. Risks of inaction include missed opportunities for clinical trials and preventive measures, as untreated amyloid buildup accelerates neurodegeneration. Deadlines are implicit in disease progression: once symptoms manifest, interventions are less effective.

Non-obvious angles emerge in implementation. While blood tests promise equity by reaching underserved areas, performance varies across ethnic groups, as seen in studies from Latin America emphasizing the need for diverse validation. Tensions arise between stakeholders—pharmaceutical firms push for broad adoption to expand drug markets, while clinicians warn against standalone use, advocating integration with neuroimaging to avoid false positives. Surprising data reveals that multimarker panels boost diagnostic accuracy to 97%, yet point-of-care versions lag in reliability for remote settings.

Trade-offs underscore the balance between speed and caution. Over-diagnosis could lead to unnecessary anxiety or treatments, especially in primary care where Roche's test is cleared for ruling out pathology. Conversely, underuse perpetuates disparities, with racial minorities underrepresented in trials despite higher dementia rates in some groups.